Thank you for posting that, most helpful
Wendywuu
My consultant is talking September but seeing as it should have started in April.....? Will we be the first non responders to try it?
Wendywuu
Hi butter4
My consultant will be running a trial this September hopefully ( if funding is there) of this new protoease inhibitor. You can read about it in post from hectorSF.. Not sure if they have any data on non responders with this drug yet but hey any glimmer of hope is good!
Good luck
Wendy wuu
Am also waiting for the same phase 3 trial of BI201335 but so far theyre only treating naieve patients, am expecting it will include non responders soon though. Results look promising from phase 2 trials.
Good Luck !
http://clinicaltrials.gov/ct2/results?term=boehringer+ingelheim+bi-201335
To : wendy and butter4...Don"t know if you already saw this or not.
http://www.pharmaceutical-networking.com/bi-201335-boehringer-ingelheims-bi-201335-hepatitis-c-compound-gets-the-green-light-for-phase-3/
Seems this Protease Inhibitor.has had very good results in previous trials.
Hope that helps ..
Will
I too have had problems with current treatments. What is B1201335?
BI 201335; Positive Phase 2 results Boehringer Ingelheim’s investigational Hepatitis C protease inhibitor
Sunday, April 3, 2011
Posted by New HCV Drugs
FILE UNDER BI 201335, EASL
Positive Phase 2 results reported with Boehringer Ingelheim’s investigational HCV protease inhibitor in both previously treated and untreated patients
BERLIN, Germany, and RIDGEFIELD, CT, April 1, 2011 – New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) demonstrate the antiviral activity of Boehringer Ingelheim's once-daily oral protease inhibitor, BI 201335, in both treatment-naïve and -experienced patients with chronic genotype-1 (GT1) hepatitis C virus (HCV), the most challenging genotype of HCV to treat. Results from SILEN-C1 show a sustained viral response (SVR) in 71 to 83 percent of treatment-naïve patients who received BI 201335 once-daily plus the current standard-of-care (SOC) [pegylated interferon (PegIFN) and ribavirin (RBV)].
Results from SILEN-C2 show an SVR in 28 to 41 percent of treatment-experienced patients who received BI 201335 once-daily plus PegIFN and RBV.
"SILEN-C1 and 2 have shown positive Phase 2 results in a broad range of HCV patients," said Peter Piliero, M.D., executive director, Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "The current standard-of-care in HCV is not effective for enough patients. Protease inhibitors such as BI 201335 represent potential new options to improve outcomes and the possibility to shorten the duration of treatment for HCV disease."
"Boehringer Ingelheim is continuing its long heritage in virology and commitment to develop new medicines for HCV," continued Piliero. "BI 201335 is part of BI's growing HCV portfolio, which is being investigated with the goal of improving treatment and cure rates for HCV patients. We are excited that we will commence our Phase 3 trial program with BI 201335 in the near future, based on the results of these Phase 2 studies."
Hectorsf